

Advancing Pharmacogenetic Testing to the **point-of-care**

Interim Results:
31 December 2023

5 April 2024

genedrive



Document information

NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. This document, which comprises a presentation of the results for the period ending 31 December 2023, has been prepared by genedrive PLC ("genedrive"). By reviewing this presentation, you agree to be bound by the following conditions. The release, presentation, publication or distribution of this presentation, in whole or in part, in certain jurisdictions may be restricted by law or regulation and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

No representation or warranty (express or implied) of any nature is given nor is any responsibility or liability of any kind accepted by genedrive or any of its directors, officers, employees, advisers, representatives or other agents, with respect to the truthfulness, completeness or accuracy of any information, projection, representation or warranty (express or implied), omissions, errors or misstatements in this presentation, or any other written or oral statement provided. None of genedrive or its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this material or otherwise in connection with this material.

Nothing contained in this presentation is intended to constitute an invitation or inducement to engage in investment activity for the purposes of the prohibition on financial promotions in section 21 of the UK Financial Services and Markets Act 2000. In making this presentation available, genedrive makes no recommendation to buy, sell or otherwise deal in shares of genedrive or in any other securities or investments whatsoever and does not constitute or form part of any offer, or an invitation to sell or issue or subscribe for or purchase any securities in nor of genedrive and you should neither rely nor act upon, directly or indirectly, any of the information contained in this presentation in respect of any such investment activity. Further, it should not be treated as giving investment, legal, accounting, regulatory, taxation or other advice. Any recipients of this presentation outside the UK should inform themselves of and observe any applicable legal or regulatory requirements in their jurisdiction and are treated as having represented that they are able to receive this presentation without contravention of any law or regulation in the jurisdiction in which they reside or conduct business. In particular, the securities referred to in this presentation have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered, sold or transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "goal", "target", "aim", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond genedrive's ability to control or predict, and future events and circumstances can cause results and developments to differ materially from those anticipated. Nothing in this presentation should be construed as a profit forecast. Forward-looking statements are not guarantees of future performance and hence may prove to be erroneous. Other than in accordance with its legal or regulatory obligations (including under the AIM Rules for Companies, Market Abuse Regulation and the Disclosure Guidance and Transparency Rules), genedrive does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation has been prepared without reference to your particular investment objectives, financial situation, taxation position and particular needs. It is important that you view this presentation in its entirety. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under the Financial Services and Markets Act 2000).

genedrive plc (LSE : GDR): Executive team

James Cheek | Chief Executive Officer

- Appointed in September 2023
- Over 20 years of commercial and operational experience in a variety of diagnostic fields.
- Prior roles with Roche, Beckman Coulter and Cepheid. Former Board Executive at BIVDA, BIVDA representative to the NHS Supply chain Board, Chair of the BIVDA procurement working party.

Russ Shaw | Chief Financial Officer

- Appointed in April 2022
- Over 25 years of international experience across multiple sectors including life-sciences, technology and the industrials.
- 10 years as Finance Director at Driver Group plc, an AIM quoted company operating in the engineering and construction industry.
- CFO of several private companies in recent years and is a qualified Accountant and Treasury professional.

Dr Gino Miele | Chief Scientific Officer

- Appointed to board as CSO September 2024
- Considerable experience in the translational genomics and development of molecular diagnostic technologies and systems. Has held position of R&D Director at genedrive since 2015 and its predecessor Epistem since 2011.
- Key driver in the development of the genedrive® system and the recent menu of pharmacogenetic tests.


Agenda

1. What we do
2. Product Development
3. MT-RNR1
4. CYP2C19
5. Summary Financials
6. News flow summary




genedrive

What we do



genedrive plc (LSE : GDR)

Where are we positioned in relation to Genomics use for precision treatments ?



Genetic variants in an individual can dictate the likelihood that a drug will be effective or not, or cause unintended harm through an adverse reaction.

genedrive plc (LSE : GDR)

The use of Pharmacogenetic testing is gaining pace : -

In the UK NHS alone –

- Expanding genetic tests within the national genomic testing directory
- Licensing of medicines with pharmacogenetic guided dosing
- NICE guidelines and assessments
- Professional body guidelines and recommendations for practice
- Core to UK NHS Genomics 5-year strategy¹

Genomics & diagnostics are key in the healthcare shift towards personalised medicines, improving patient outcomes & reducing costs.



Genedrive® Product Development status



Genedrive® System



- Low cost, rapid, touchscreen operated thermocycler
- Permitting sample to result in ~26mins (MT-RNR1) & ~70mins (CYP2C19)
- Positioned outside of core laboratories, at point-of-care in emergency healthcare paradigms
- Proprietary core chemistry;
 - No requirement for sample preparation (nucleic acid extraction)
 - No requirement for cold chain logistics for transport or use
- Electronic patient record integration

MT-RNR1 ID (AIHL - Antibiotic Induced Hearing Loss)



Swab



Mix



Transfer



Reconstitute
Assay



Run Test

NICE National Institute for Health and Care Excellence

Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

Health technology evaluation
Published: 30 March 2023

NICE National Institute for Health and Care Excellence

Evidence-generation plan for Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies

Published: 10 August 2023

NIHR National Institute for Health and Care Research



Office for
Life Sciences

Real World
Evidence
Programme

- World's first point of care pharmacogenetic test for AIHL in NICU settings
- NICE recommendation for use in NHS whilst further evidence generated
- NICE evidence generation requirements published
- NIHR/OLS funding application for consortia led programmes to address NICE EVA requirements submitted (1st Oct.'24 start date if successful)
 - 18-month programme duration, including 14 hospital sites of different tier settings across the UK
 - Submission to NICE to seek change in guidance from conditional to full can be made earlier as soon as evidence is generated

MT-RNR1 ID (AIHL - Antibiotic Induced Hearing Loss)



Swab



Mix



Transfer



Reconstitute
Assay



Run Test

NICE National Institute for Health and Care Excellence
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

Health technology evaluation
Published: 30 March 2023

NICE National Institute for Health and Care Excellence
Evidence-generation plan for Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies

Published: 10 August 2023

NIHR National Institute for Health and Care Research



Office for Life Sciences
Real World Evidence Programme

- No predicate test in USA for this paradigm
 - Unique challenges associated with this required interaction with FDA on how to generate evidence & what would be viewed as satisfactory
- FDA expectations for evidencing performance & safety clear, with *de novo* submission route to be pursued.
 - Required US Clinical group partner in final contractual stages
 - International Biomedical contracted as US distributor
 - Anticipated start in late 2024 (subject to funding)

CYP2C19 ID



NICE National Institute for
Health and Care Excellence

CYP2C19 genotype testing to guide
clopidogrel use after ischaemic
stroke or transient ischaemic attack
In development [GID-
DG10054] Expected publication
date: 10 July 2024

- Only known point of care test that identifies **six** DNA variants in the CYP2C19 gene that are responsible for ineffective metabolism of the drug Clopidogrel
- Some of these variants whilst rare in general population are higher frequency in certain ethnic groups
- NICE recommend CYP2C19 genotyping in IS/TIA within 24hrs prior to administration of clopidogrel
 - Preliminary draft recommendation of Genedrive CYP2C19 test for point of care testing in NHS (Final guidance to be issued in July)
 - ✓ *Maximal ethnicity coverage*
 - ✓ *No requirement for fridges and freezers*
 - ✓ *Electronic health record integration*
 - ✓ *Dominant cost effectiveness in health economic modelling*



NICE National Institute for
Health and Care Excellence

CYP2C19 genotype testing to guide
clopidogrel use after ischaemic
stroke or transient ischaemic attack
In development [GID-
DG10054] Expected publication
date: 10 July 2024

- NICE UK guidance is for CYP2C19/Clopidogrel use in IS/TIA
 - Clopidogrel ranked #37 in top drug use in US in 2021 (includes non-IS/TIA), with 4.2M patients & 17M prescription events¹
- Non-clopidogrel alternative (Ticagrelor) whilst not impacted by CYP2C19 is more expensive, has increased bleeding risks and does not have marketing authorisation for use in preventing further TIA or strokes in the UK²
- UKCA certified, permitting UK commercialisation
- Innovate funded DEVOTE programme for clinical validation is underway and once completed UK commercialisation efforts will commence
 - Also generates data required for submission for CE-IVD certification (early 2025) and non-UK commercialisation




Genedrive® MT-RNR1 ID Kit

**Antibiotic Induced
Hearing Loss
(AIHL)**



AIHL - Antibiotic Induced Hearing Loss

Total Addressable Market Estimate = £100M



Model assumptions:

- International - Extrapolated from population sizes, birth rates, and UK admission to NICU rate
- Based direct sale model

**Approximately 100K UK
NICU admissions**

**Addressable Global Market
>£100m**

CE-IVD Certified

**Positive
Health Economic Case in
place and being developed**

**NICE recommendation
(conditional)
NICE EVA evidence
generation plan**

**Final stage contractual
process for strategic
partner & distributor in US
for FDA submission
process**


genedrive

**Genedrive®
CYP2C19-ID Kit**



Genedrive® CYP2C19-ID Kit

Total Addressable Market Estimate = £220M



Model assumptions:

- UK - Based on NICE prevalence of stroke
- International – Europe AHA journals USA – CDC
- Row – assumes <10% developed healthcare markets

**Addressable Market
for ischemic strokes.**

**100K strokes
per year in the UK**

**~30,000 UK patients could
get better health outcome**

**Collaboration under
Innovate funded DEVOTE
program, saving >£1m in
validation costs for CE-IVD**


**Full NICE
recommendation (draft)
for use in NHS**

**DEVOTE clinical study
(UK) underway**

Market

- ~12 million strokes per year globally¹
 - ~100,000 per year in UK
 - ~38,000 stroke related
- Stroke incidence per annum in the UK predicted to increase by 60% between 2015 and 2035²
- In an estimated 30% of patients, some antiplatelet drugs prescribed for stroke management are ineffective
- Pharmacogenetic/Pharmacogenomic testing is mainly performed in labs on expensive equipment but the advance of point of care testing is changing this due to the speed and closeness to the patient
 - UK minimum result turnaround time from Genetic hubs 2 days with averages far higher
- There are currently only 7 genomic hubs in England – NICE guidance for CYP2C19 testing in IS/TIA is 24 hours

Summary Financials



Summary Financials - Income statement

Income statement	Dec-23 (6 months) £'000	Dec-22 (6 months) £'000	Jun-23 (12 months) £'000
Revenue and other income	238	21	55
R&D costs	(1,876)	(1,988)	(3,924)
Admin costs	(721)	(713)	(1,355)
Operating loss	(2,359)	(2,680)	(5,224)
Finance costs	(30)	(11)	(757)
Loss before tax	(2,389)	(2,691)	(5,981)
Tax	350	500	831
Loss after tax	(2,039)	(2,191)	(5,150)


- Revenue and other income increased >£0.2m
- R&D spend reduced £0.1m as we focused on near-commercialisation product development
- Admin costs at similar levels due to continued tight cost management
- Tax credit reflects reduction in HMRC R&D tax relief rates

Summary Financials – Cashflow

Cashflow	Dec-23 (6 months) £'000	Dec-22 (6 months) £'000	Jun-23 (12 months) £'000
Operating loss before changes in working capital	(2,201)	(2,533)	(4,874)
Working capital	(217)	126	113
Taxation	-	-	956
Net cashflow from operations	(2,418)	(2,407)	(3,805)
Proceeds from investment funding	1,200	-	2,300
Transaction costs - investment funding	(48)	-	(283)
Other	(109)	(99)	(200)
Net cash flow	(1,375)	(2,506)	(1,988)
Cash at bank b/f	2,601	4,589	4,589
Cash at bank c/f	1,226	2,083	2,601
Underlying monthly burn rate:	(421)	(418)	(413)

- Operating loss before changes in working capital is £0.3m less than H1-23 due to increased income and reduced costs
- Working capital consumed £0.2m related mainly to movement in creditors
- £1.2m received from the Investor Placing Agreement
- Unaudited cash at 20 March 2024 of £1.2m, following £0.8m receipt of R&D tax credit
- Underlying cash consumption of c£0.4m
- Cash runway remains as set out in interim results

News flow summary



News flow summary

Near Term

- Revenue from additional go-live sites in the UK and abroad for MT RNR1
- Continue progressing special commissioning for MT RNR1
- Finalise position for FDA registration requirements for MT RNR1
- Further NICE data gathering for full recommendation commences MT RNR1
- Completion of DEVOTE clinical study for CYP2C19 for CE-IVDR accreditation
- Start UK Sales and Marketing activity for CYP2C19 and research use only sales outside the UK.
- Continuation of instrument design improvements to facilitate adoption, and expansion of test menu expansion
- Future funding activities to support FDA studies/regulatory review, product development and expected growth

Medium to Long Term

- Commence IVDR registration for CYP2C19 (~July 2024), expectation of CE-IVD approval (early 2025)
- Launch of CYP2C19 in non-UK territories following CE-IVD certification
- Commence FDA registration for MT RNR1
- Commence business cases for future target pipeline tests